A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL.

This document provides information about a clinical trial, NCT06428019, that aims to evaluate the safety and effectiveness of different drug combinations for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The trial will involve approximately 120 adult participants with CLL at 80 sites worldwide. The study will assess adverse events, changes in disease activity, and the effects of oral venetoclax in combination with either intravenously infused obinutuzumab or oral acalabrutinib. Regular visits, medical assessments, blood tests, and questionnaires will be conducted to monitor the treatment's effects. The trial is expected to be completed by October 2026, and data sharing is planned. [Extracted from the article]